Levi & Korsinsky announces it has commenced an investigation of ACADIA Pharmaceuticals Inc. (“ACADIA” or “the Company”) (NASDAQGS: ACAD) concerning possible violations of federal securities laws. On April 9, 2018, ACADIA stock fell after CNN issued a report stating that “Physicians, medical researchers and other experts told CNN that they worried that the drug [NUPLAZID] had been approved too quickly, based on too little evidence that it was safe or effective.” On April 10, 2018, the Food and Drug Administration stated it would continue to monitor reports of adverse events. Then on July 9, 2018, a report was published by The Southern Investigative Reporting Foundation alleging that ACADIA’s “pursuit of regulatory approval is best described as ‘loophole-centric’.” To obtain additional information on the ACADIA class action investigation (ACAD class action investigation), go to: http://www.zlk.com/pslra-d/acadia-investigation or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.